DK1052254T3 - Nitrogen-holdig heterocykliske derivater og medicin deraf - Google Patents

Nitrogen-holdig heterocykliske derivater og medicin deraf

Info

Publication number
DK1052254T3
DK1052254T3 DK99900654.7T DK99900654T DK1052254T3 DK 1052254 T3 DK1052254 T3 DK 1052254T3 DK 99900654 T DK99900654 T DK 99900654T DK 1052254 T3 DK1052254 T3 DK 1052254T3
Authority
DK
Denmark
Prior art keywords
group
alkyl group
atom
substituted
ring
Prior art date
Application number
DK99900654.7T
Other languages
English (en)
Inventor
Kazuki Miyazaki
Yasutaka Takase
Takao Saeki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of DK1052254T3 publication Critical patent/DK1052254T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
DK99900654.7T 1998-01-26 1999-01-21 Nitrogen-holdig heterocykliske derivater og medicin deraf DK1052254T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10013062A JPH11209350A (ja) 1998-01-26 1998-01-26 含窒素複素環誘導体およびその医薬
PCT/JP1999/000215 WO1999037622A1 (en) 1998-01-26 1999-01-21 Nitrogenous heterocyclic derivatives and medicine thereof

Publications (1)

Publication Number Publication Date
DK1052254T3 true DK1052254T3 (da) 2011-09-12

Family

ID=11822661

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99900654.7T DK1052254T3 (da) 1998-01-26 1999-01-21 Nitrogen-holdig heterocykliske derivater og medicin deraf

Country Status (9)

Country Link
US (2) US6352989B1 (da)
EP (1) EP1052254B1 (da)
JP (2) JPH11209350A (da)
AT (1) ATE512955T1 (da)
CA (1) CA2318579C (da)
DK (1) DK1052254T3 (da)
ES (1) ES2367413T3 (da)
PT (1) PT1052254E (da)
WO (1) WO1999037622A1 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395520A1 (en) 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
DE10043667A1 (de) * 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
BR0116231A (pt) 2000-12-20 2004-03-02 Merck & Co Inc Método de formação de uma mistura do produto de reação
JP4310109B2 (ja) * 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
GB0128109D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7608716B2 (en) * 2002-11-06 2009-10-27 Aska Pharmaceutical Co., Ltd. Pyrazolonaphthyridine derivative
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
MXPA05011103A (es) 2003-04-16 2005-12-12 Hoffmann La Roche Compuestos de quinazolina.
DE602004008762T2 (de) * 2003-04-30 2008-06-12 The Institutes for Pharmaceutical Discovery, LLC, Branford Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
JPWO2005040135A1 (ja) * 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
AU2005245386B2 (en) * 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
US20080085858A1 (en) * 2004-10-13 2008-04-10 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical Composition
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
JP2008137892A (ja) * 2005-03-04 2008-06-19 Eisai Co Ltd 止痒剤
DE102005022977A1 (de) * 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
TWI404709B (zh) 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
AU2007218725B2 (en) * 2006-02-21 2011-12-01 Eisai R & D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
JP5102230B2 (ja) * 2007-02-16 2012-12-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 メチルn−[3−(6,7−ジメトキシ−2−メチルアミノキナゾリン−4−イル)フェニル]テレフタラミックアシッドの結晶、非晶質体または塩
WO2008099887A1 (ja) 2007-02-16 2008-08-21 Eisai R & D Management Co., Ltd. メチル n-[3-(6,7-ジメトキシ-2-メチルアミノキナゾリン-4-イル)フェニル]テレフタラミックアシッドの結晶、非晶質体または塩
US8530654B2 (en) 2007-02-16 2013-09-10 Eisai R&D Management Co., Ltd. Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid
KR20090118025A (ko) * 2007-02-16 2009-11-17 에자이 알앤드디 매니지먼트 가부시키가이샤 메틸 n-[3-(6,7-디메톡시-2-메틸아미노퀴나졸린-4-일)페닐]테레프탈람산의 결정, 비정질체 또는 염
CN101687818B (zh) * 2007-02-19 2012-08-22 卫材R&D管理有限公司 甲基n-[3-(6,7-二甲氧基-2-甲氨基喹唑啉-4-基)苯基]对氨羰基苯甲酸的结晶、无定形物或盐
CN101687820B (zh) * 2007-08-17 2012-07-25 卫材R&D管理有限公司 喹唑啉衍生物的制造方法
CN101687819B (zh) 2007-08-17 2013-03-20 卫材R&D管理有限公司 外用剂
EP2367801A1 (en) * 2008-11-19 2011-09-28 Wyeth LLC Polar quinazolines as liver x receptors ( lxrs ) modulators
AU2011311238A1 (en) 2010-10-05 2013-04-04 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
AU2013235038A1 (en) 2012-03-21 2014-10-09 Malvika Kaul Antimicrobial agents
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11201503620RA (en) * 2012-11-08 2015-06-29 Univ Rutgers Antimicrobial agents
WO2014133020A1 (ja) * 2013-02-28 2014-09-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 呼吸器疾患の予防治療剤
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
EP3237397B1 (en) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
CN109195957A (zh) 2016-02-25 2019-01-11 塔克西斯医药股份有限公司 合成方法和中间体
JP2019519543A (ja) 2016-06-07 2019-07-11 デルマヴァント サイエンシーズ ゲーエムベーハーDermavant Sciences Gmbh Pde−4阻害剤の局所処方物およびそれらの使用方法
CA3058183A1 (en) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates towardthe production of txa709
US11344543B2 (en) * 2017-07-14 2022-05-31 Innate Tumor Immunity, Inc. NLRP3 modulators
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
CN115260164B (zh) * 2021-05-01 2024-03-26 杭州星鳌生物科技有限公司 新型4(3h)-喹唑啉酮类似物的制备方法、结构组成及其在抗肿瘤药物中的应用
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4020866B1 (da) 1963-12-18 1965-09-16
FR2514765A1 (fr) 1981-10-21 1983-04-22 Sanofi Sa Nouveaux derives de la phenyl-4 quinazoline actifs sur le systeme nerveux central
JPH02299987A (ja) 1989-05-15 1990-12-12 Naomasa Nomura 自動車の遠心力による可変ホイール
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
JP3042156B2 (ja) 1992-02-20 2000-05-15 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
JPH06192099A (ja) 1992-10-07 1994-07-12 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
WO1994007498A1 (fr) 1992-10-07 1994-04-14 Sumitomo Pharmaceuticals Company, Limited Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale
JP3033090B2 (ja) 1995-06-15 2000-04-17 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
DE60008206T2 (de) * 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase

Also Published As

Publication number Publication date
JP4132666B2 (ja) 2008-08-13
ES2367413T3 (es) 2011-11-03
WO1999037622A1 (en) 1999-07-29
US20020055516A1 (en) 2002-05-09
EP1052254A1 (en) 2000-11-15
JPH11209350A (ja) 1999-08-03
CA2318579A1 (en) 1999-07-29
EP1052254A4 (en) 2008-03-05
EP1052254B1 (en) 2011-06-15
CA2318579C (en) 2008-11-25
ATE512955T1 (de) 2011-07-15
US6800644B2 (en) 2004-10-05
US6352989B1 (en) 2002-03-05
PT1052254E (pt) 2011-09-05

Similar Documents

Publication Publication Date Title
EP1052254A4 (en) NITROGENIC HETEROCYCLIC DERIVATIVES AND DRUGS PRODUCED FROM SUCH DERIVATIVES
EA200000842A1 (ru) Бицикло [2.2.1] гептаны и родственные соединения
EA200200299A1 (ru) НОВЫЕ α-АМИНОКИСЛОТНЫЕ СУЛЬФОНИЛЬНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ИХ СОДЕРЖАЩИЕ
ATE368655T1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
NO20023097D0 (no) Heterocykliske forbindelser med sulfonamidgrupper
DE69514367D1 (de) Substituierte amidderivate
ATE126802T1 (de) Heterocyclische derivate.
EA200300792A1 (ru) Хиназолины в качестве ингибиторов ммр-13
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
CY1110904T1 (el) Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun
DK1065204T3 (da) Bicykliske carbonyl-indolforbindelser som anti-inflammatoriske/analgesiske midler og som COX-2-inhibitorer
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
DE60307179D1 (de) Vor UV-Strahlen schützende Zusammensetzungen
EA200100090A3 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
ATE366248T1 (de) N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
DK1106614T3 (da) 5-leddede, heteroarylsubstituerede 1,4-dihydropyridinforbindelser som bradykininantagonister
DK0485219T3 (da) Lægemidler til forebyggelse og behandling af kredsløbsorgansygdomme indeholdende spiro-3-heteroazolidinforbindelser
DE60107836D1 (de) Triazolderivate mit amidbindungen
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
ATE449773T1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
EA200500028A1 (ru) Новые соединения 3-(4-оксо-4h-хромен-2-ил)-(1h)-хинолин-4-она, способ их получения и фармацевтические композиции, которые их содержат
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
EA200200379A3 (ru) Новые соединения пиримидин-4-она, способ их получения и содержащие их фармацевтические композиции
DE69714709D1 (de) Cyclische amic-säurederivate